研友_LmeK4L
Lv4
415 积分
2020-08-03 加入
-
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study
9天前
已完结
-
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
9天前
已完结
-
The present and future of bispecific antibodies for cancer therapy
17天前
已完结
-
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
18天前
已完结
-
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
18天前
已完结
-
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
18天前
已完结
-
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
21天前
已完结
-
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
22天前
已完结
-
Lymph node resection does not impair cancer immunotherapy responses
22天前
已完结
-
Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?
23天前
已完结
-
内容是前列腺癌的 不是130这篇研究
18天前
-
只有两张图
3个月前
-
很长时间【积分已退回】
7个月前
-
不是这篇呢,是这篇https://www.sciencedirect.com/science/article/pii/S2059702923008219
7个月前
-
不需要了【积分已退回】
1年前
-
文献信息错误【积分已退回】
1年前
-
第一作者是ProfSibylleLoiblMD
2年前
-
The Lancet
Available online 1 April 2021
Breast cancer
Summary
Breast cancer is still the most common cancer worldwide. But the way breast cancer is viewed has changed drastically since its molecular hallmarks were extensively characterised, now including immunohistochemical markers (eg, ER, PR, HER2 [ERBB2], and proliferation marker protein Ki-67 [MKI67]), genomic markers (eg, BRCA1, BRCA2, and PIK3CA), and immunomarkers (eg, tumour-infiltrating lymphocytes and PD-L1). New biomarker combinations are the basis for increasingly complex diagnostic algorithms.
是昨天柳叶刀刚出的 不是书
2年前
-
不是这篇文献
2年前
-
不是原文,这篇是会议摘要
2年前